USPSTF: Docs should talk with high-risk women about breast cancer drugs

09/24/2013 | Reuters

The U.S. Preventive Services Task Force has released a statement recommending that physicians talk with women at high risk of developing breast cancer about drugs that might reduce their risk. Tamoxifen or raloxifene interfere with the effects of estrogen in breast tissue, but they are associated with side effects including blood clot risk.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD